Surgical Treatment of Bisphosphonate-associated Osteonecrosis of the Jaw: Technical Report and Follow Up of 21 Patients
Overview
General Surgery
Authors
Affiliations
Introduction: Bisphosphonates are used to reduce skeletal related events in patients with bone consuming diseases such as osteoporosis and bone metastases. However recently there has been an increased awareness of bisphosphonate-associated necrosis of the jaws (BP-ONJ). Many authors propose conservative management in these cases but invariably the problem is not treated successfully allowing the bone defect to worsen. Recently there has been a move to treat this problem surgically. The aim of this retrospective study was to provide a surgical solution for patients suffering from BP-ONJ.
Materials And Methods: All patients presenting with BP-ONJ were treated with bone debridement of the affected area and multilayer wound closure. The considered variables were: gender, age, underlying diagnosis, type of bisphosphonate (BP) used, duration of bisphosphonate use, route of administration, location of the osteonecrosis, clinical symptoms, association with dental treatment and surgical outcome.
Results: Nineteen cases of a total of 21 demonstrated no recurrence of osteonecrosis during follow up (Mean 16 months - Range 12-24 months). One patient with a bilateral defect showed a dehiscence on one side and a small fistula on the contralateral side 6 weeks post-operatively and required revision surgery. Another patient developed a fistula after 4 weeks that was treated successfully with antibiotics and curettage. No patients had evidence of exposed bone, bland mucosa nor pain at the surgical site.
Conclusion: The technique described can be recommended for patients with BP-ONJ if a conservative treatment fails.
How we manage medication-related osteonecrosis of the jaw.
Byrne H, OReilly S, Weadick C, Brady P, Riordain R Eur J Med Res. 2024; 29(1):402.
PMID: 39095845 PMC: 11297747. DOI: 10.1186/s40001-024-01912-6.
Sacco R, Sartoretto S, de Brito Resende R, Calasans-Maia J, Rossi A, De Souza Lima V Medicina (Kaunas). 2023; 59(1).
PMID: 36676670 PMC: 9861076. DOI: 10.3390/medicina59010046.
Gaudet C, Odet S, Meyer C, Chatelain B, Weber E, Parmentier A Cells. 2022; 11(24).
PMID: 36552861 PMC: 9777472. DOI: 10.3390/cells11244097.
Bullock G, Miller C, McKechnie A, Hearnden V Front Oral Health. 2022; 2:822411.
PMID: 35224540 PMC: 8865370. DOI: 10.3389/froh.2021.822411.
CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ.
Marciano A, Ieni A, Mauceri R, Oteri G Int J Environ Res Public Health. 2021; 18(21).
PMID: 34769880 PMC: 8582901. DOI: 10.3390/ijerph182111362.